JACKSONVILLE, Fla., Oct. 28, 2022 —RedDress, a privately held U.S. and Israel-based global medical device company, today announced the release of the new ActiGraft+® system – the next generation of their wound management system. ActiGraft+, FDA-cleared, is an enhancement of the original technology designed to shorten the coagulation time and produce a higher-quality topically applied blood clot.
“When developing ActiGraft+, we wanted to improve the current process while still maintaining the same outcomes clinicians are relying on,” said Alon Kushnir, Chief Executive Officer of RedDress. “This new solution demonstrates our commitment to delivering an advanced technology that is designed to handle the needs of clinicians while also improving the patient experience.”
Nearly 7 million Americans are living with chronic wounds. To support clinicians and patients manage these complex wounds, RedDress developed ActiGraft. ActiGraft creates in vitro blood clots from a patient’s own blood. Once applied, the blood clot serves as a protective covering and promotes the body’s natural wound-healing response. ActiGraft+ is clinically backed and when used on diabetic foot ulcers, delivers a 72.2% complete healing rate in 12 weeks1.
The original ActiGraft® system was launched in the fall of 2020. Since then, over 40 countries have adopted the use of ActiGraft in their care setting, including the United Kingdom, Canada, Brazil, Hong Kong and South Africa. For more information on where ActiGraft is available, visit https://reddressmedical.com/distributor-map/.
About the Suite of ActiGraft Products
ActiGraft and ActiGraft+, based on RedDress’ proprietary patented technology, are FDA-cleared wound care solutions that enable health care providers to produce – in real time – an in vitro blood clot from a patient’s whole blood. Once applied, the blood clot serves as a protective covering and supports wound healing processes which naturally occur in the patient’s body.
ActiGraft and ActiGraft+ are intended for exuding cutaneous wounds. The systems include blood-contacting components that have been sterilized by Ethylene Oxide, which may cause serious allergic reactions in patients that are sensitized. For full prescribing information, visit www.reddressmedical.com/safety-info.
About RedDress
RedDress (www.reddressmedical.com) is a privately held, Israel-based company with a U.S. subsidiary, RedDress Inc., located in Ponte Vedra Beach, Florida. Founded in 2009 with the goal of developing more effective, natural, and economically viable treatments for chronic wounds, we’re proud to expand our suite of products to include ActiGraft and our latest innovation – ActiGraft+.
###
ActiGraft® system is a registered trademark of RedDress Ltd.
ActiGraft+® system is a registered trademark of RedDress Ltd.
1 Snyder RJ, Kasper MA, Patel K, Carter MJ, Kushnir I, Kushnir A, Serena TE. Safety and Efficacy of an Autologous Blood Clot Product in the Management of Texas 1A or 2A Neuropathic Diabetic Foot Ulcers: A Prospective, Multicenter, Open Label Pilot Study. Wounds. 2018 Jul;30(7):84-89. Epub 2018 Apr 20. PMID: 29718812.